Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04057573
Study type Interventional
Source Incyte Corporation
Contact
Status Completed
Phase Phase 3
Start date October 3, 2019
Completion date October 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT04052425 - Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) Phase 3
Completed NCT04942860 - The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo Phase 3
Recruiting NCT06113328 - A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007) Phase 2
Recruiting NCT01377077 - Punchgrafting Techniques for Vitiligo Phase 4
Completed NCT04927975 - Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo Phase 2
Completed NCT04487860 - Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo Phase 2
Active, not recruiting NCT04811326 - Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation Phase 4
Terminated NCT03022019 - ReNovaCell in Non-segmental Vitiligo N/A
Completed NCT03247400 - The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo Phase 1/Phase 2
Not yet recruiting NCT05990309 - ASSESSMENT OF TRISTETRAPROLIN EXPRESSION IN LESIONAL SKIN OF PATIENTS WITH NON SEGMENTAL VITILIGO N/A